{"id":2572,"date":"2018-03-06T21:22:42","date_gmt":"2018-03-06T15:52:42","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2572"},"modified":"2021-07-24T12:56:56","modified_gmt":"2021-07-24T07:26:56","slug":"notizia-latest-pharma-news-2","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2","title":{"rendered":"NOTIZIA"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Dermira pulling plug on acne drug after phase 3 failure<\/strong><\/p>\n<p style=\"text-align: justify;\">Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. The mechanism of action of the drug was on targeting the overproduction of sebum.<\/p>\n<p style=\"text-align: justify;\"><strong>Stem cells providing insight on potential anti-Alzheimer\u2019s compound<\/strong><\/p>\n<p style=\"text-align: justify;\">It is found that toxic deposits of the proteins amyloid beta and tau in the brain have been associated with Alzheimer\u2019s disease, but the exact role of these proteins in causing dementia is still unknown. A group of scientists at the University of Washington is using stem cells from patients suffering from Alzheimer\u2019s patients to study the two proteins.<\/p>\n<p style=\"text-align: justify;\"><strong>USFDA accepted for the review of Dupixent as a potential treatment for moderate-to-severe Asthma<\/strong><\/p>\n<p style=\"text-align: justify;\">FDA has recently accepted for review of the supplemental Biologics License Application of Dupixent. It will be reviewed as an add-on maintenance treatment for certain adults and adolescents (12 years of age and older) suffering from moderate-to-severe asthma. As per the Prescription Drug User Fee Act, the target action date is set on October 20, 2018.<\/p>\n<p style=\"text-align: justify;\"><strong>Novartis and Pear Therapeutics entered into a collaboration to develop digital therapeutics<\/strong><\/p>\n<p style=\"text-align: justify;\">Novartis and Pear Therapeutics has recently entered into a collaboration to develop novel prescription digital therapeutics. Software applications are designed to treat the disease more effectively and improve clinical outcomes for patients. With This collaboration, Novartis and Pear Therapeutics are taking advantage of their expertise in biomedical research, clinical development, digital therapeutics design and implementation.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Dermira pulling plug on acne drug after phase 3 failure Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. The [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2465,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[1118,204,349,1230,639,706],"industry":[17225],"therapeutic_areas":[17237,17245,17243],"class_list":["post-2572","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-business-research","tag-delveinsight","tag-latest-pharma-news","tag-pharma-consultancy","tag-pharma-news","tag-pharmaceutical-industry","industry-pharmaceutical","therapeutic_areas-dermatology","therapeutic_areas-neurology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Notizia- Delveinsight Business research latest pharma industry News<\/title>\n<meta name=\"description\" content=\"Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after missing primary endpoints in a pair of phase 3 trials.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Notizia- Delveinsight Business research latest pharma industry News\" \/>\n<meta property=\"og:description\" content=\"Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after missing primary endpoints in a pair of phase 3 trials.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-03-06T15:52:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1112\" \/>\n\t<meta property=\"og:image:height\" content=\"660\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Notizia- Delveinsight Business research latest pharma industry News","description":"Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after missing primary endpoints in a pair of phase 3 trials.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2","og_locale":"en_US","og_type":"article","og_title":"Notizia- Delveinsight Business research latest pharma industry News","og_description":"Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after missing primary endpoints in a pair of phase 3 trials.","og_url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-03-06T15:52:42+00:00","article_modified_time":"2021-07-24T07:26:56+00:00","og_image":[{"width":1112,"height":660,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2","url":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2","name":"Notizia- Delveinsight Business research latest pharma industry News","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","datePublished":"2018-03-06T15:52:42+00:00","dateModified":"2021-07-24T07:26:56+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after missing primary endpoints in a pair of phase 3 trials.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/notizia-latest-pharma-news-2#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia.png","width":1112,"height":660,"caption":"transthyretin amyloidosis"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2017\/12\/09021225\/Notizia-300x178.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Latest pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma news<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Latest pharma news<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">pharma news<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 6, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 6, 2018 9:22 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"transthyretin amyloidosis","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2572","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2572"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2572\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2465"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2572"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2572"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2572"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2572"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2572"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}